Reliable quality of Lamivudine 134678-17-4 with fast deliveryLamivudine API GMP CAS NO.134678-17-4
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Product Details
Keywords
- Reliable quality of Lamivudine
- 134678-17-4 with fast delivery
- Lamivudine API GMP
Quick Details
- ProName: Reliable quality of Lamivudine 134678-...
- CasNo: 134678-17-4
- Molecular Formula: C8H11N3O3S
- Appearance: White or almost white crystalline soli...
- Application: HIV, HBV
- DeliveryTime: 10 days after ordering
- PackAge: Two-layer LDPE bag and All Paper Drum
- Port: Any port in China
- ProductionCapacity: 500 Metric Ton/Year
- Purity: 98.0%~102.0%
- Storage: Below 30°C.
- Transportation: as per request
- LimitNum: 1 Kilogram
- Grade: Pharma Grade
Superiority
Reliable quality of Lamivudine 134678-17-4 with fast deliveryLamivudine API GMP
Trade name: Lamivudine; He puding
Product category: Pharmaceutical raw materials
Product content: 99%
CAS No. : 134678-17-4
Quality standard: USP26
Description: white crystal or crystalline powder
Molecular formula: C8H11N3O3S (2R-cis) -4-amino-1 - (2-hydroxymethyl-1, 3-oxythiocycloval-5-yl) -1h-pyrimidine-2-ketone
Molecular weight: 229.25
CAS: 134678-17-4
Appearance: white solids obtained from methanol-ethyl acetate, or crystallized from boiling ethanol
Melting point: 160 ~ 162℃
Refractive index: -142 ° (C=1, MeOH)
Lamivudine can be metabolized in HBV-infected cells and normal cells to produce lamivudine triphosphate. It is the active form of lamivudine, which is not only an inhibitor of HBV polymerase, but also a substrate of this
polymerase. Lamivudine triphosphate is incorporated into the viral DNA chain, blocking the synthesis of viral DNA, and does not interfere with the metabolism of deoxynucleosides in normal cells. It has a weak inhibitory effect on mammalian DNA polymerases α and β, and it has a weak inhibitory effect on mammals. The cell DNA content has almost no effect. It has no obvious toxicity to the structure, DNA content and function of mitochondria. The test results of serum HBV-DNA in most patients with hepatitis B indicate that lamivudine can rapidly inhibit HBV replication, and its inhibitory effect continues throughout the treatment process. At the same time, the serum transaminase can be reduced to normal, and long-term application can significantly improve the inflammatory changes of liver necrosis and reduce or prevent the progress of liver fibrosis.
Details
[New antiviral drugs]
Lamivudine is a new antiviral drug, belonging to nucleoside reverse transcriptase inhibitors, which has a strong inhibitory effect on hepatitis B virus (HBV) in vitro and in experimental infected animals, and can inhibit the synthesis of HIV virus. The drug is made by glaxosmithKline PLC.In the early 1990s, the drug was used to treat AIDS in some countries in Europe and North America. In the mid-1990s, medical experts found that it had an inhibitory effect on THE DNA of hepatitis B virus. In 1998, the Food and Drug Administration (FDA) first approved the drug as a treatment for hepatitis B.The drug was approved by the State Food and Drug Administration of the Chinese mainland to be imported mainly for hepatitis B treatment. The Chinese commercial name of the drug is "Hepuding", and it was officially sold in the Chinese mainland in 1999.
After 10 years of clinical trials, Lamivudine is the only drug that has been shown to slow the progression of hepatitis cirrhosis, with fewer side effects and less cost, and is currently being used by 2 million hepatitis B patients nationwide.